ClinicalTrials.gg

Program

zelpultide alfa

Also written as “AT-100” and “Zelpultide alfa”.

Its studies are mostly in Bronchopulmonary Dysplasia · COVID-19, led by Airway Therapeutics.

Furthest: phase 3, since Feb 20, 20253 company-led studies, 1 open or runningNext primary completion: Mar 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Airway Therapeutics31 open or runningphase 3since Feb 20, 2025Dec 4, 2020Mar 31, 2028phase 3 · NCT06897839

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 4, 2020First studies: 2 phase 1 studiesFirst studyNCT04662151, NCT04659122
  2. Feb 20, 2025Phase 3 study in Bronchopulmonary DysplasiaNCT06897839 · 366 planned · Argentina, Belgium, France and more

Ahead

  1. Mar 31, 2028Primary completion: phase 3 study in Bronchopulmonary DysplasiaNCT06897839

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06897839Bronchopulmonary Dysplasia · Argentina, Belgium, France and more3RecruitingMar 31, 2028366
NCT04662151Bronchopulmonary Dysplasia · United States, Spain1CompletedAug 14, 202337
NCT04659122COVID-19 · United States1TerminatedFeb 23, 20235

How it is read

Names in the registry

  • “AT-100”, 2 entries
  • “Zelpultide alfa”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.